Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q06643 (non-Hodgkin's lymphoma)
 11,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Serum soluble Interleukin-2 receptor levels (sIL-2R) were measured in 121 patients (pts) with non-Hodgkin's lymphoma (NHL) and in 30 patients with Chronic lymphocytic leukemia (CLL). Sera collected from 32 normal volunteers and 18 patients with infection or a variety of non malignant hematological disorders served as controls. A small number of patients with Hairy cell leukemia (HCL) and Hodgkin's disease (HD) were also studied. NHL patients were classified according to their clinical status as "active" (82 pts) or "non-active" (39 pts) and CLL according to the stage of their disease. NHL patients were also further classified as low (55 pts), intermediate (38 pts) and high grade malignancy (28 pts), according to the Working formulation scheme. A significant difference was found between the high levels of sIL-2R in patients with "active" disease and the lower levels in patients with quiescent or responsive disease. Significantly different high levels were found in patients with aggressive (intermediate and high grade) lymphoma as opposed to low grade lymphoma and CLL. In CLL itself higher levels of sIL-2R were seen in more advanced disease than in early disease. Thirteen patients with active Hodgkin's disease (HD) had moderately elevated sIL-2R levels, similar to those recorded for patients with infections and some non-malignant hematological disorders while another 13 HD patients in remission, had normal levels comparable to those recorded in normal controls. Extremely high levels of sIL-2R were seen in 2 patients with HD with severe viral infections and levels approaching those seen in HCL, were noted (20-30,000 u/ml).(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Serum soluble interleukin-2 receptor levels are associated with clinical disease status and histopathological grade in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. 149 44

We examined 19 non-Hodgkin's lymphoma patients for their responsiveness to lectin stimulation, as measured by T cell proliferative response and p55kDa-IL2R expression. Our results indicate that both these responses were remarkably depressed in non-Hodgkin's lymphoma patients and the deficiency of lectin-induced p55kDa-IL2R expression correlated closely with the reductions in the lectin-induced T cell proliferative responses. The evidence that costimulation with PMA can partially overcome the IL2R defect might allow us to localize the cellular defects and rationally design chemotherapeutic agents corrective for these patients' poor p55kDa-IL2R inducibility.
 ...
PMID:Defective lectin-induced p55kDa-IL2R expression on peripheral T cells in non-Hodgkin's lymphoma patients. 183 88

A cell line, SCC-3, was established from the pleural fluid of a patient with non-Hodgkin's lymphoma. Interleukin-2 receptor (IL2-R) was found to be expressed on the cell surface by marker analysis, and morphological, cytochemical, and other marker analyses suggested a monocytic lineage. SCC-3 may be useful for studies on the role of IL2-R in monocytic cells.
 ...
PMID:Establishment and characterization of a monocytic cell line which expresses the interleukin-2 receptor. 309 81